Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is a large market cap stock with a market cap of 10618.78. It is in the Drug Delivery industry and sector Healthcare, with a current P/E of *TBA, a forward P/E of 4 and EPS of -2.86. At a stock price of 30.83 (-0.84%) it has a dividend yield of *TBA.
EPS growth for the last five years have been 4.40%, more recently this last year it has grown by -133.00%. The next year growth is going to be about 17.94% and more long-term 11.07% after five years. EPS growth quarter over quarter is *TBA. Sales growth for the past five years have been 54.60% and sales growth quarter over quarter is -68.30%.
For performance, Valeant Pharmaceuticals International, Inc. the past week has seen a gain of 7.27%. For the last month performance for Valeant Pharmaceuticals International, Inc. is 33.29%. While the last quarter is 8.48% and half year, -53.15%. Finally for the year, performance is -86.88%.
The 52-week high for Valeant Pharmaceuticals International, Inc., is at -87.46%, and for the 52-week low it comes to a value of 66.20%. The 20-day simple moving average is 29.45% and -42.26% for the 200-day simple moving average.
Volatility for the week is at 5.74%, and for the month it is 5.88%. Valeant Pharmaceuticals International, Inc., has a target price of 44.39.
In terms of debt, long term debt/equity is 5.81, and for total debt/equity Valeant Pharmaceuticals International, Inc. has 5.87. The gross margin is 74.70%, while operating margin is 7.70%, the profit margin is -9.60%. The current ratio is 1.4 and the quick ratio is 1.1.
Insider ownership is at 2.30%, with instituitional ownership at 66.80%. Valeant Pharmaceuticals International, Inc. has a payout ratio of *TBA. With the total shares outstanding coming to 344.43. The shares float is 332.63, with the float short at 9.93%, with short ratio coming to 1.09.
In terms of returns, the return on assets see Valeant Pharmaceuticals International, Inc., get -2.00%, with its returns on investment at 3.70%. Return on equity is -17.00%. So will the investors see the target price of 44.39, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.